Literature DB >> 24490813

Role of Toll-like receptors in diabetic nephropathy.

Harshini Mudaliar1, Carol Pollock1, Usha Panchapakesan1.   

Abstract

Diabetic nephropathy is the leading cause of kidney failure and its increasing prevalence and incidence has imposed global socio-economic stress on healthcare systems worldwide. Although historically considered a metabolic disorder, recent studies have established that inflammatory responses are central to the pathogenesis of diabetic nephropathy. TLRs (Toll-like receptors) are a family of pattern recognition receptors responsible for the initiation of inflammatory and immune responses. The regulation of TLR2 and TLR4 have been implicated in the pathogenesis of various kidney diseases, and emerging evidence shows their involvement in the perpetuation of inflammation in the diabetic kidney. The present review focuses on the relative contributions of TLR2 and TLR4 in recognizing endogenous ligands relevant to diabetic nephropathy and their subsequent activation of NF-κB (nuclear factor κB), which results in the synthesis and secretion of pro-inflammatory cytokines and chemokines. Moreover, we discuss the pro-inflammatory signalling pathways of TLR2 and TLR4, in which their interruption or blockade may prove to be important therapeutic targets, potentially translated into clinical treatments for diabetic nephropathy. Currently, inhibitors to TLR2 and TLR4 are undergoing clinical trials in various inflammatory models of disease, but none in patients with diabetic nephropathy. Given the existing literature, there is a fundamental necessity to undertake trials in patients with diabetic nephropathy with a focus on renal end points.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24490813     DOI: 10.1042/CS20130267

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  20 in total

Review 1.  Targeting gut microbiota: a potential promising therapy for diabetic kidney disease.

Authors:  Zhonge Chen; Shuishan Zhu; Gaosi Xu
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

Review 2.  Non-genetic mechanisms of diabetic nephropathy.

Authors:  Qiuxia Han; Hanyu Zhu; Xiangmei Chen; Zhangsuo Liu
Journal:  Front Med       Date:  2017-09-04       Impact factor: 4.592

3.  Linagliptin reduces effects of ET-1 and TLR2-mediated cerebrovascular hyperreactivity in diabetes.

Authors:  Trevor Hardigan; Yasir Abdul; Adviye Ergul
Journal:  Life Sci       Date:  2016-02-17       Impact factor: 5.037

4.  The transcription factor Twist1 in the distal nephron but not in macrophages propagates aristolochic acid nephropathy.

Authors:  Jiafa Ren; Nathan P Rudemiller; Yi Wen; Xiaohan Lu; Jamie R Privratsky; Steven D Crowley
Journal:  Kidney Int       Date:  2019-08-13       Impact factor: 10.612

Review 5.  Insights into the Mechanisms Involved in the Expression and Regulation of Extracellular Matrix Proteins in Diabetic Nephropathy.

Authors:  C Hu; L Sun; L Xiao; Y Han; X Fu; X Xiong; X Xu; Y Liu; S Yang; F Liu; Y S Kanwar
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

Review 6.  Innate immunity in diabetes and diabetic nephropathy.

Authors:  Jun Wada; Hirofumi Makino
Journal:  Nat Rev Nephrol       Date:  2015-11-16       Impact factor: 28.314

7.  Caspase-1, but Not Caspase-3, Promotes Diabetic Nephropathy.

Authors:  Khurrum Shahzad; Fabian Bock; Moh'd Mohanad Al-Dabet; Ihsan Gadi; Shrey Kohli; Sumra Nazir; Sanchita Ghosh; Satish Ranjan; Hongjie Wang; Thati Madhusudhan; Peter P Nawroth; Berend Isermann
Journal:  J Am Soc Nephrol       Date:  2016-02-01       Impact factor: 10.121

8.  Diminution of microRNA-98 alleviates renal fibrosis in diabetic nephropathy by elevating Nedd4L and inactivating TGF-β/Smad2/3 pathway.

Authors:  Yi Zeng; Zhijian Feng; Yunjuan Liao; Ming Yang; Yihua Bai; Zhenkun He
Journal:  Cell Cycle       Date:  2020-12-14       Impact factor: 4.534

9.  Paeoniflorin attenuates incipient diabetic nephropathy in streptozotocin-induced mice by the suppression of the Toll-like receptor-2 signaling pathway.

Authors:  Yun-Xia Shao; Xing-Xin Xu; Kun Wang; Xiang-Ming Qi; Yong-Gui Wu
Journal:  Drug Des Devel Ther       Date:  2017-11-09       Impact factor: 4.162

10.  CCL24 Protects Renal Function by Controlling Inflammation in Podocytes.

Authors:  Youdi Wang; Xue Wu; Mengya Geng; Jiamin Ding; Kangjia Lv; Hui Du; Jiahui Ding; Wenjun Pei; Xin Hu; Jing Gu; Lizhuo Wang; Yao Zhang; Jialin Gao
Journal:  Dis Markers       Date:  2021-06-16       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.